Program
DW4902
A development code. Also written as “DW4902 160mg”, “DW4902 240mg” and “DW4902 320mg”.
Its studies are mostly in Myoma, led by Daewon Pharmaceutical.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Daewon Pharmaceutical | 10 open or running | phase 2since Dec 22, 2025 | Dec 22, 2025 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 22, 2025First study: phase 2 study in Myoma of UterusFirst studyNCT07319520 · 71 enrolled · South Korea
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07319520Myoma of Uterus · South Korea | 2 | Completed | Nov 11, 2024 | 71 |
How it is read
Names in the registry
- “DW4902 160mg”, 1 entry
- “DW4902 240mg”, 1 entry
- “DW4902 320mg”, 1 entry
Codes read as this program: DW4902.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.